As of writing, studies in laboratory animals have not identified significant safety concerns [3, 4]
La mayora de protocolos de investigacin en esta categora operan sobre biomarcadores intermedios (expresin gnica, marcadores inflamatorios, parmetros dermatolgicos) porque los endpoints duros estn fuera del horizonte temporal viable
We proposed to specify under new 425.600(h)(1)(iii) that an ACO determined to be inexperienced with performance-based risk Medicare ACO initiatives but which is not eligible to enter the BASIC track's glide path, in accordance with the provisions of 425.600(h)(1), may enter BASIC track Level E for all performance years of the agreement period, or the ENHANCED track, subject to the proposed exception prohibiting ACOs with fewer than 5,000 assigned beneficiaries in BY1, BY2, or both, from participating in the ENHANCED track specified in new 425.600(h)(3) (described in section III.F.4.b.(2).(b) of the CY 2026 PFS proposed rule)
[6] At present, NAD+ Injection has no well-defined absolute contraindications aside from hypersensitivity to NAD+ or any ingredient in the formulation
